On Friday, Carisma Therapeutics Inc (NASDAQ: CARM) opened lower -43.81% from the last session, before settling in for the closing price of $0.27. Price fluctuations for CARM have ranged from $0.14 to $1.27 over the past 52 weeks.
During the last 5-year period, the sales growth of Healthcare Sector giant was 42.71%. Company’s average yearly earnings per share was noted 52.74% at the time writing. With a float of $25.38 million, this company’s outstanding shares have now reached $41.79 million.
Carisma Therapeutics Inc (CARM) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Carisma Therapeutics Inc is 39.27%, while institutional ownership is 4.28%. The most recent insider transaction that took place on Oct 07 ’25, was worth 14,485. In this transaction Chief Scientific Officer of this company sold 56,982 shares at a rate of $0.25, taking the stock ownership to the 0 shares. Before that another transaction happened on Oct 07 ’25, when Company’s OFFICER proposed sale 56,982 for $0.25, making the entire transaction worth $14,183.
Carisma Therapeutics Inc (CARM) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.31 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.36) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 52.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 32.95% during the next five years compared to 42.71% growth over the previous five years of trading.
Carisma Therapeutics Inc (NASDAQ: CARM) Trading Performance Indicators
Check out the current performance indicators for Carisma Therapeutics Inc (CARM). In the past quarter, the stock posted a quick ratio of 0.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.18, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.52 in one year’s time.
